Diagnostic options · UAE

Cancer Mutation Panel tests in Dubai & UAE

Compare available Cancer Mutation Panel tests, their listed prices and the information provided for each option. Test selection and preparation should be discussed with your clinician.

Tests in this category

Listed price range

750.00–4,800.00 AED

Clinical preparation

Confirm test-specific instructions with your clinician or laboratory.

Compare available tests

Cancer Mutation Panel test prices

Showing 1–5 of 5 matching tests.

Cancer Mutation Panel diagnostic tests, details, and listed prices
Test and description	Specimen	Typical duration	Price	Options
TEST-656 Chronic Lymphocytic Leukemia (CLL) Mutations Detection Panel 1 Test This test identifies key genetic mutations and deletions associated with Chronic Lymphocytic Leukemia (CLL). It provides crucial information for risk stratification and treatment p...	Whole Blood (EDTA Tube)	5 Days (Sample Mon, Report Sat)	750.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["TP53 (17p deletion)", "ATM (11q deletion)", "Other clinically significant loci"] Parameters [] Preparation ["Fasting is not required.", "Avoid heavy physical exertion and alcohol consumption for 24 hours prior to sampling.", "A completed Genomics Clinical Information Requisition Form (Form 20) is mandatory."] Indications ["Diagnosis of CLL", "Prognosis assessment in CLL", "Guidance for targeted therapy selection in CLL"] Measurement technique Confirm with laboratory Codes LOINC: 101467-8 ICD-10: C91.1 Clinical summary This test identifies key genetic mutations and deletions associated with Chronic Lymphocytic Leukemia (CLL). It provides crucial information for risk stratification and treatment planning.
TEST-1695 Colorectal Cancer Panel (NRAS, KRAS, BRAF) Test This test identifies mutations in the NRAS, KRAS, and BRAF genes within colorectal tumor tissue.	Formalin-fixed paraffin-embedded (FFPE) tissue block or fresh tumor biopsy	7–8 working days	3,600.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["NRAS gene mutations", "KRAS gene mutations", "BRAF gene mutations"] Parameters [] Preparation ["No fasting or special preparation is needed"] Indications ["Patients with colorectal adenocarcinoma", "Patients being considered for anti-EGFR therapy"] Measurement technique Confirm with laboratory Codes LOINC: 101596-7 ICD-10: C18.9, C19, C20 Clinical summary This test identifies mutations in the NRAS, KRAS, and BRAF genes within colorectal tumor tissue.
TEST-1411 Lung Cancer Mutation Panel 5 (EGFR, KRAS, BRAF, ALK1, ROS1) Test This diagnostic test evaluates for the presence of specific genetic mutations (EGFR, KRAS, BRAF, ALK1, ROS1) in formalin-fixed paraffin-embedded (FFPE) tumor tissue.	Formalin-Fixed Paraffin-Embedded (FFPE) Tumor Tissue Block or Archival Slides	5–7 working days	4,800.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["EGFR gene mutations", "KRAS gene mutations", "BRAF gene mutations", "ALK1 gene rearrangements", "ROS1 gene rearrangements"] Parameters [] Preparation ["No fasting or special preparation is required from the patient."] Indications ["Diagnosis of non-small cell lung cancer (NSCLC)", "Guidance for targeted therapy selection in NSCLC", "Prediction of treatment response in NSCLC"] Measurement technique Confirm with laboratory Codes LOINC: 93024-1 ICD-10: C34.9, Z85.1 Clinical summary This diagnostic test evaluates for the presence of specific genetic mutations (EGFR, KRAS, BRAF, ALK1, ROS1) in formalin-fixed paraffin-embedded (FFPE) tumor tissue.
TEST-1424 Lung Cancer Panel 2 (EGFR, ALK1, ROS1) Mutation Analysis Test This test identifies specific genetic mutations (EGFR, ALK1, ROS1) in non-small cell lung cancer (NSCLC) tissue samples.	Formalin-Fixed Paraffin-Embedded (FFPE) Tumour Tissue Block / Archival Biopsy Slides	5–7 working days	3,000.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["EGFR mutations (Exon 19 deletions, L858R point mutations)", "ALK gene rearrangements", "ROS1 fusions"] Parameters [] Preparation [] Indications ["Histologically confirmed NSCLC diagnosis", "Prior to initiating first-line tyrosine kinase inhibitor therapy", "Upon disease progression to assess resistance mechanisms"] Measurement technique Confirm with laboratory Codes LOINC: 92815-7 ICD-10: C34.90 Clinical summary This test identifies specific genetic mutations (EGFR, ALK1, ROS1) in non-small cell lung cancer (NSCLC) tissue samples.
TEST-1421 Lung Cancer Panel 4: EGFR, ALK, ROS1, MET & PD‑L1 Test This diagnostic test evaluates five key biomarkers (EGFR, ALK, ROS1, MET, PD-L1) in tumor tissue to guide targeted therapy and immunotherapy selection for non-small cell lung cance...	Tumor Tissue (FFPE Block or Biopsy Slides)	5–7 business days	4,000.00 AED	View
View test specifications and preparation Hide test specifications and preparation What it measures ["EGFR mutations", "ALK rearrangements", "ROS1 rearrangements", "MET alterations (fusions/amplifications)", "PD-L1 expression"] Parameters [{"name": "EGFR", "reference_range": "Qualitative (Mutations detected/not detected)"}, {"name": "ALK", "reference_range": "Qualitative (Rearrangement detected/not detected)"}, {"name": "ROS1", "reference_range": "Qualitative (Rearrangement detected/not detected)"}, {"name": "MET", "reference_range": "Qualitative (Fusions/Amplifications detected/not detected)"}, {"name": "PD-L1", "reference_range": "Qualitative (Expression level %)"}] Preparation ["No special patient preparation is needed beyond clinician’s pre-biopsy instructions."] Indications ["Diagnosis of non-small cell lung cancer", "Treatment planning for metastatic or advanced non-small cell lung cancer", "Identifying eligibility for targeted therapies or immunotherapies"] Measurement technique Confirm with laboratory Codes LOINC: 60513-6 ICD-10: C34.9 Clinical summary This diagnostic test evaluates five key biomarkers (EGFR, ALK, ROS1, MET, PD-L1) in tumor tissue to guide targeted therapy and immunotherapy selection for non-small cell lung cancer.

Category overview

Cancer Mutation Panel: overview

Confronting a cancer diagnosis requires the most accurate information possible, and understanding your tumor's specific genetic alterations provides the ultimate foundation for proactive care. As part of our Molecular Diagnostics division, our Cancer Mutation Panel testing employs high-throughput next-generation sequencing to simultaneously evaluate critical cancer-driving mutations. Rather than acting as a definitive standalone diagnosis, this expansive cancer mutation panel data empowers your oncologist with the exact insights needed for targeted therapies and highly customized medical guidance. Trusted among leading diagnostic labs in Dubai and the UAE, DNA Labs UAE guarantees uncompromising patient confidentiality coupled with exceptionally swift, precise turnaround times. Empower your targeted oncology strategy: review our cancer mutation panel testing in the UAE below to book an appointment, schedule a seamless home sample collection, or consult our dedicated specialists.

Before booking

Use the test details as a conversation starter

The right diagnostic option depends on your reason for testing and individual circumstances. Check the listed specimen and timing, then confirm any preparation requirements with the ordering clinician or laboratory before collection.